Unknown

Dataset Information

0

ZRSR2 loss causes aberrant splicing in JAK2<sup>V617F</sup>-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.

ABSTRACT:

SUBMITTER: Zhang R 

PROVIDER: S-EPMC12439484 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

ZRSR2 loss causes aberrant splicing in JAK2&lt;sup&gt;V617F&lt;/sup&gt;-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.

Zhang Ranran R   Straube Jasmin J   Janardhanan Yashaswini Y   Haldar Rohit R   Cooper Leanne L   Hayes Noah N   Laurore Charles C   Kim Chulwoo J CJ   Luskin Marlise R MR   Lindsley Robert C RC   Stahl Maximilian M   Mullally Ann A   Marneth Anna E AE   Bywater Megan M   Lane Steven W SW  

HemaSphere 20250916 9

Similar Datasets

Unknown Oncogenic JAK2&lt;sup&gt;V617F&lt;/sup&gt; causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.
| S-EPMC6034655 | biostudies-literature
Unknown &lt;i&gt;JAK2&lt;/i&gt; &lt;sup&gt;V617F&lt;/sup&gt; Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic Clones.
| S-EPMC12485877 | biostudies-literature
Unknown NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasm cells.
| S-EPMC6978524 | biostudies-literature
Unknown Inherited polygenic effects on common hematological traits influence clonal selection on JAK2&lt;sup&gt;V617F&lt;/sup&gt; and the development of myeloproliferative neoplasms.
| S-EPMC10864174 | biostudies-literature
Unknown Reversine exhibits antineoplastic activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasms.
| S-EPMC6616334 | biostudies-literature
Unknown JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
| S-EPMC3138766 | biostudies-literature
Unknown Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
| S-EPMC9470591 | biostudies-literature
Unknown Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2<sup>V617F</sup> myeloproliferative neoplasms.
| S-EPMC10330179 | biostudies-literature
Transcriptomics ZRSR2-loss causes aberrant splicing in a JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression
2025-02-02 | GSE225396 | GEO
Unknown Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
| S-EPMC3536786 | biostudies-literature